Sun Pharmaceutical Industries Past Earnings Performance
Past criteria checks 5/6
Sun Pharmaceutical Industries has been growing earnings at an average annual rate of 28.5%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 10.4% per year. Sun Pharmaceutical Industries's return on equity is 16%, and it has net margins of 22%.
Key information
28.5%
Earnings growth rate
28.6%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 10.4% |
Return on equity | 16.0% |
Net Margin | 22.0% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sun Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 503,077 | 110,541 | 96,684 | 0 |
30 Jun 24 | 492,088 | 103,895 | 95,551 | 0 |
31 Mar 24 | 484,969 | 95,764 | 95,025 | 0 |
31 Dec 23 | 474,446 | 89,063 | 93,681 | 0 |
30 Sep 23 | 463,049 | 85,485 | 90,419 | 0 |
30 Jun 23 | 450,648 | 84,352 | 86,821 | 0 |
31 Mar 23 | 438,857 | 84,736 | 83,549 | 0 |
31 Dec 22 | 424,018 | 42,119 | 80,549 | 0 |
30 Sep 22 | 410,239 | 41,047 | 78,688 | 0 |
30 Jun 22 | 396,975 | 38,894 | 76,169 | 0 |
31 Mar 22 | 386,545 | 32,727 | 73,544 | 0 |
31 Dec 21 | 377,307 | 64,441 | 71,354 | 0 |
30 Sep 21 | 367,044 | 62,378 | 70,049 | 0 |
30 Jun 21 | 356,316 | 60,036 | 68,619 | 0 |
31 Mar 21 | 334,981 | 29,038 | 69,042 | 0 |
31 Dec 20 | 331,601 | 24,095 | 68,729 | 0 |
30 Sep 20 | 324,782 | 14,706 | 67,016 | 0 |
30 Jun 20 | 320,484 | 7,219 | 65,810 | 0 |
31 Mar 20 | 328,375 | 37,649 | 63,986 | 0 |
31 Dec 19 | 318,165 | 40,010 | 64,149 | 0 |
30 Sep 19 | 314,018 | 43,293 | 63,608 | 0 |
30 Jun 19 | 302,161 | 29,956 | 62,101 | 0 |
31 Mar 19 | 290,659 | 26,654 | 61,027 | 0 |
31 Dec 18 | 288,052 | 34,379 | 58,539 | 0 |
30 Sep 18 | 277,182 | 24,380 | 57,316 | 0 |
30 Jun 18 | 275,048 | 35,690 | 54,702 | 0 |
31 Mar 18 | 264,155 | 20,957 | 54,814 | 0 |
31 Dec 17 | 263,811 | 20,763 | 54,007 | 0 |
30 Sep 17 | 276,530 | 31,827 | 52,432 | 0 |
30 Jun 17 | 295,310 | 45,057 | 49,929 | 0 |
31 Mar 17 | 313,081 | 69,644 | 50,285 | 0 |
31 Dec 16 | 319,185 | 73,270 | 49,986 | 0 |
30 Sep 16 | 311,431 | 74,000 | 49,212 | 0 |
30 Jun 16 | 297,512 | 61,937 | 48,012 | 0 |
31 Mar 16 | 281,086 | 45,457 | 49,076 | 0 |
31 Dec 15 | 266,281 | 38,915 | 95,369 | 0 |
30 Sep 15 | 264,670 | 28,702 | 95,000 | 0 |
30 Jun 15 | 276,422 | 38,150 | 45,608 | 0 |
31 Mar 15 | 273,920 | 45,394 | 46,483 | 0 |
31 Dec 14 | 170,765 | 59,141 | 45,586 | 0 |
30 Sep 14 | 170,835 | 60,202 | 45,036 | 0 |
30 Jun 14 | 165,250 | 58,100 | 44,680 | 0 |
31 Mar 14 | 160,804 | 31,415 | 44,040 | 0 |
31 Dec 13 | 150,933 | 26,104 | 35,071 | 0 |
Quality Earnings: 524715 has high quality earnings.
Growing Profit Margin: 524715's current net profit margins (22%) are higher than last year (18.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524715's earnings have grown significantly by 28.5% per year over the past 5 years.
Accelerating Growth: 524715's earnings growth over the past year (29.3%) exceeds its 5-year average (28.5% per year).
Earnings vs Industry: 524715 earnings growth over the past year (29.3%) exceeded the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: 524715's Return on Equity (16%) is considered low.